

<b>FORM PTO-1449</b> <b>(Rev. 2-32)</b>  <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>SECOND SUPPLEMENTAL</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)	<b>Atty. Docket No.</b>  04-218 (400.148)	<b>Serial No.</b>  10/800,487
	<b>Applicant:</b> McSwiggen et al.	
	<b>Filing Date:</b>  March 15, 2004	<b>Group:</b>  1635

### U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
	*	US-2002/0086356	03/30/01	Tuschl et al.			07/04/02
	*	US-2003/0059944	09/13/02	Lois-Caballe et al.			03/27/03
	*	US-2003/0064945	07/25/01	Akhtar et al.			04/03/03
	*	US-2003/0143732	08/30/02	Fosnaugh et al.			07/31/03
	*	US-2003/0190635	07/25/02	McSwiggen et al.			10/09/03
	*	US-2003/0206887	09/16/02	Morrissey et al.			11/06/03
	*	US-2004/0019001	07/26/02	McSwiggen et al.			01/29/04
	*	US-2004/0161844	11/04/03	Baker et al.			08/19/04
	*	US-2005/0020521	09/25/05	Rana, Tariq M.			01/27/05
	*	US-2005/0182005	05/13/04	Tuschl et al.			02/18/05
	*	US-2005/0227256	11/26/04	Hutvagner et al.			10/13/05

### U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	*	5,587,471	12/24/96	Cook et al.			
	*	5,998,148	12/07/99	Bennett et al.			

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> <b>(Rev. 2-32)</b>  <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>SECOND SUPPLEMENTAL</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)	<b>Atty. Docket No.</b>  04-218 (400.148)	<b>Serial No.</b>  10/800,487
	<b>Applicant:</b> McSwiggen et al.	
	<b>Filing Date:</b>  March 15, 2004	<b>Group:</b>  1635

	*	5,998,206	12/07/99	Cowsert			
	*	6,060,456	05/09/00	Arnold et al.			
	*	6,214,805	04/10/01	Torrence et al.			
	*	6,346,398	02/12/02	Pavco et al.			
	*	6,573,099	06/03/03	Graham et al.			
	*	6,824,972	11/30/04	Kenwrick et al.			
	*	7,022,828	04/04/06	McSwiggen et al.			
	*	7,078,196	07/18/06	Tuschl et al.			

### FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclasses	Translation	
							Yes	No
	1.	1389637	08/05/02	EP (Klippel et al.)				
	2.	2003/044188	11/21/02	WO (Tei et al.)				
	3.	04/029212	04/08/04	WO (Rana, Tariq M.)				
	4.	04/043977	05/27/04	WO (Prakush et al.)				
	5.	04/048566	11/21/03	Saigo et al.				
	6.	04/090105	10/21/04	WO (Leake et al.)				

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> <b>(Rev. 2-32)</b>  <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>SECOND SUPPLEMENTAL</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)	<b>Atty. Docket No.</b>  04-218 (400.148)	<b>Serial No.</b>  10/800,487
	<b>Applicant:</b> McSwiggen et al.	
	<b>Filing Date:</b>  March 15, 2004	<b>Group:</b>  1635

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).**

7.	Alexeev et al., "Localized in vivo genotypic and phenotypic correction of the albino mutation in skin by RNA-DNA oligonucleotide," <i>Nature Biotechnology</i> , 18:43-47 (2000)
8.	Bellon et al., "4-Thio-oligo- $\beta$ -D-ribonucleotides: synthesis of $\beta$ -4'-thio-oligouridylates, nuclease resistance, base pairing properties, and interaction with HIV-1 reverse transcriptase," <i>Nucleic Acids Research</i> , 21(7):1587-1593 (1993)
9.	Bernstein et al., "The rest is silence," <i>RNA</i> , 7:1509-1521 (2001)
10.	Bitko et al., "Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses," <i>BMC Microbiology</i> , 1:34 (11 pgs) (2001)
11.	Braasch et al., "Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression," <i>Biochemistry</i> , 31:14, 4503-4510 (2002)
12.	Braasch et al., "RNA Interference in Mammalian Cells by Chemically-Modified RNA," <i>Biochemistry</i> , 42, 7967-7975 (2003)
13.	Claverie, Jean-Michel, "Fewer Genes, More Noncoding RNA," <i>Science</i> , 309, 1529-1530 (2005)
14.	Clemens et al., "The Double-Stranded RNA-Dependent Protein Kinase PKR: Structure and Function," <i>Journal of Interferon and Cytokine Research</i> , 17:503-524 (1997)
15.	Czech, Michael P., "MicroRNAs as Therapeutic Targets," <i>The New England Journal of Medicine</i> , 354, 1194-1195 (2006)
16.	Elbashir et al., "Analysis of gene function in somatic mammalian cells using small interfering RNAs," <i>Methods</i> , 26:199-213 (2002)
17.	Hamasaki et al., "Short interfering RNA-directed inhibition of hepatitis B virus replication," <i>FEBS Letters</i> , 543:51-54 (2003)
18.	Harborth et al., "Sequence, Chemical, and Structural Variation of Small Interfering RNAs and Short Hairpin RNAs and the Effect on Mammalian Gene Silencing," <i>Antisense and Nucleic Acid Drug Development</i> , 13:83-105 (2003)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> <b>(Rev. 2-32)</b>	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b> 04-218 (400.148)	<b>Serial No.</b> 10/800,487
<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		<b>Applicant:</b> McSwiggen et al.	
		<b>Filing Date:</b> March 15, 2004	<b>Group:</b> 1635

19.	Holen et al., "Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor," <i>Nucleic Acids Research</i> , 30:8, 1757-1766 (2002)
20.	Hornung et al., "Sequence-specific potent induction of IFN- $\alpha$ by short interfering RNA in plasmacytoid dendritic cells through TLR7," <i>Nature Medicine</i> , 11, 263-270 (2005)
21.	Judge et al., "Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA," <i>Nature Biotechnology</i> , 23(4):457-462 (2005)
22.	Kawaski et al., "Uniformly Modified 2'-Modified 2'-Deoxy-2'-fluoro Phosphorothioate Oligonucleotides as Nuclease-Resistant Antisense Compounds with High Affinity and Specificity for RNA Targets," <i>J. Med. Chem.</i> , 36, 831-841 (1993)
23.	Mattick, John S., "The Functional Genomics of Noncoding RNA", <i>Science</i> , 309, 1527-1528 (2005)
24.	McCaffrey et al., "RNA interference in adult mice," <i>Nature</i> , 148, 38-39 (2002)
25.	Monia et al., "Evaluation of 2'-Modified Oligonucleotides Containing 2'-Deoxy Gaps as Antisense Inhibitors of Gene Expression," <i>J. Biol. Chem.</i> 268:14514-14522 (1993)
26.	Morvan et al., "Comparative Evaluation of Seven Oligonucleotide Analogues as Potential Antisense Agents," <i>J. Med. Chem.</i> , 36, 280-287 (1993)
27.	Olie et al., "Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL antisense oligonucleotide," <i>Biochimica et Biophysica Acta</i> , 1576, 101-109 (2002)
28.	Opalinska et al., "Nucleic-Acid Therapeutics: Basic Principles and Recent Applications," <i>Nature Reviews Drug Discovery</i> , (1):503-514 (2002)
29.	Sethupathy et al., "TarBase: A comprehensive database of experimentally supported animal microRNA targets," <i>RNA</i> , 12:192-197 (2006)
30.	Thomson et al., "Activity of hammerhead ribozymes containing non-nucleotidic linkers," <i>Nucleic Acids Research</i> 21:5600-5603 (1993) (MAY BE REFERRED TO AS THOMPSON)
31.	Zhang et al., "Single Processing Center Models for Human Dicer and Bacterial RNase III," <i>Cell</i> , 118:57-68 (2004)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.